KR20180002674A - 글리코스아미노글리칸 에스테르, 그의 제조 방법 및 눈에 사용하기 위한 제형물에서의 그의 용도 - Google Patents

글리코스아미노글리칸 에스테르, 그의 제조 방법 및 눈에 사용하기 위한 제형물에서의 그의 용도 Download PDF

Info

Publication number
KR20180002674A
KR20180002674A KR1020177032142A KR20177032142A KR20180002674A KR 20180002674 A KR20180002674 A KR 20180002674A KR 1020177032142 A KR1020177032142 A KR 1020177032142A KR 20177032142 A KR20177032142 A KR 20177032142A KR 20180002674 A KR20180002674 A KR 20180002674A
Authority
KR
South Korea
Prior art keywords
glycosaminoglycan
ester
apocarotonoid
solution
apocarotenoid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020177032142A
Other languages
English (en)
Korean (ko)
Inventor
니클라 바리코르디
로베르토 메리기
Original Assignee
하이알블루 에스.알.엘.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 하이알블루 에스.알.엘. filed Critical 하이알블루 에스.알.엘.
Publication of KR20180002674A publication Critical patent/KR20180002674A/ko
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0069—Chondroitin-4-sulfate, i.e. chondroitin sulfate A; Dermatan sulfate, i.e. chondroitin sulfate B or beta-heparin; Chondroitin-6-sulfate, i.e. chondroitin sulfate C; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0072—Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/03—Monocarboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
KR1020177032142A 2015-04-07 2016-04-07 글리코스아미노글리칸 에스테르, 그의 제조 방법 및 눈에 사용하기 위한 제형물에서의 그의 용도 Ceased KR20180002674A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITFI2015A000102 2015-04-07
ITFI20150102 2015-04-07
PCT/IB2016/051960 WO2016162809A1 (en) 2015-04-07 2016-04-07 Glycosaminoglycan esters, processes for their preparation and their use in formulations for ophthalmic use

Publications (1)

Publication Number Publication Date
KR20180002674A true KR20180002674A (ko) 2018-01-08

Family

ID=53719816

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177032142A Ceased KR20180002674A (ko) 2015-04-07 2016-04-07 글리코스아미노글리칸 에스테르, 그의 제조 방법 및 눈에 사용하기 위한 제형물에서의 그의 용도

Country Status (12)

Country Link
US (1) US10328097B2 (cg-RX-API-DMAC10.html)
EP (1) EP3280396B1 (cg-RX-API-DMAC10.html)
JP (1) JP6847091B2 (cg-RX-API-DMAC10.html)
KR (1) KR20180002674A (cg-RX-API-DMAC10.html)
CN (1) CN107636020A (cg-RX-API-DMAC10.html)
AU (1) AU2016244391B2 (cg-RX-API-DMAC10.html)
BR (1) BR112017021608A2 (cg-RX-API-DMAC10.html)
CA (1) CA2981861A1 (cg-RX-API-DMAC10.html)
ES (1) ES2888648T3 (cg-RX-API-DMAC10.html)
MA (1) MA41912A (cg-RX-API-DMAC10.html)
RU (1) RU2726192C2 (cg-RX-API-DMAC10.html)
WO (1) WO2016162809A1 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT202000012535A1 (it) * 2020-05-27 2021-11-27 Stefano Colombo Composizione oftalmica a base di acido ialuronico per la protezione dai danni causati dall’inquinamento ambientale
WO2022094695A1 (en) 2020-11-03 2022-05-12 Institut National De La Recherche Scientifique A method and a system for compressed ultrafast tomographic imaging
CN116284495B (zh) * 2023-03-20 2024-08-30 润辉生物技术(威海)有限公司 全反式维甲酸低分子透明质酸酯衍生物及其制备方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4851521A (en) * 1985-07-08 1989-07-25 Fidia, S.P.A. Esters of hyaluronic acid
IT1281877B1 (it) * 1995-05-10 1998-03-03 Fidia Advanced Biopolymers Srl Sali di metalli pesanti di succinil derivati dell'acido ialuronico e loro impiego come potenziali agenti terapeutici
ITTS20010017A1 (it) * 2001-07-17 2003-01-17 Ct Ricerche Polytech Soc Coop Esteri polisaccaridici di acido retinoico.
ITMI20022745A1 (it) * 2002-12-23 2004-06-24 Coimex Scrl United Companies Esteri misti dell'acido ialuronico ad attivita' citostatica e prodifferenziante e procedimento per la loro produzione.
ITMI20030043A1 (it) * 2003-01-14 2004-07-15 Coimex S C R L United Companies Uso di esteri retinoici dell'acido ialuronico in cellule
WO2005077176A1 (en) * 2004-02-11 2005-08-25 The Trustees Of Columbia University In The City Of New York Anthocyanin compounds and methods of use thereof
ITMI20040347A1 (it) * 2004-02-26 2004-05-26 Pharma Medical Ltd Nuovo farmaco di associazione
US20070207116A1 (en) * 2006-03-01 2007-09-06 Brown David C Antioxidant compositions for the eye
ITMI20062134A1 (it) * 2006-11-08 2008-05-09 Cbb Net S A Preparaziobne di esteri della diacereina con acido ialuronico e loro formulazioni per l'impiego farmaceutico
US8865685B2 (en) * 2011-06-30 2014-10-21 Johnson & Johnson Vision Care, Inc. Esters for treatment of ocular inflammatory conditions
CA2886115A1 (en) * 2012-10-02 2014-04-10 Allergan, Inc. Dermal filler hydrogels with vitamin a/cyclodextrin inclusion complexes

Also Published As

Publication number Publication date
EP3280396A1 (en) 2018-02-14
AU2016244391A1 (en) 2017-11-23
JP2018510962A (ja) 2018-04-19
CA2981861A1 (en) 2016-10-13
ES2888648T3 (es) 2022-01-05
AU2016244391B2 (en) 2020-11-19
US10328097B2 (en) 2019-06-25
CN107636020A (zh) 2018-01-26
RU2017138283A (ru) 2019-05-07
MA41912A (fr) 2018-02-13
WO2016162809A1 (en) 2016-10-13
JP6847091B2 (ja) 2021-03-24
BR112017021608A2 (pt) 2018-07-03
RU2017138283A3 (cg-RX-API-DMAC10.html) 2019-09-30
EP3280396B1 (en) 2021-06-23
RU2726192C2 (ru) 2020-07-09
US20180117077A1 (en) 2018-05-03

Similar Documents

Publication Publication Date Title
KR102539060B1 (ko) 만누론 이산의 조성물
CN101514177A (zh) 从万寿菊颗粒中提取叶黄素的方法
JP6978325B2 (ja) キサントフィルとヒシ属植物の加工物を含有する組成物
EP3280396B1 (en) Glycosaminoglycan esters, processes for their preparation and their use in formulations for ophthalmic use
KR20180011777A (ko) 망막 색소 상피 세포를 보호하기 위한 노르빅신 함유 조성물
KR20100092925A (ko) 어류 정액 또는 알로부터 분리된 dna 중합체 단편복합체를 포함하는 세포활성 강화용 조성물, 및 얼굴 또는 피부 충진제
CN108484795B (zh) 硫酸软骨素锂及其制备方法和应用
JP2021080270A (ja) キサントフィルとヒシ属植物の加工物を含有する組成物
WO2025092626A1 (zh) 一类工程细胞及应用
CN112996799B (zh) 包含来源于决明子芽的萘并吡喃酮衍生物的神经细胞保护用组合物
CN111202746B (zh) 一种眼用复合制剂及其制备方法
EA023370B1 (ru) Хондроитинсульфат акульего типа и способ его получения
JP2015507070A (ja) 部分的に解重合したグリコサミノグリカン銀及び金塩
CN112641944A (zh) 一种卟啉-抗菌肽超分子纳米抗菌水凝胶及其制备方法和应用
RU2568597C1 (ru) Фотосенсибилизатор и способ его получения
JP6688498B2 (ja) プロテオグリカンの分解方法及び分解物
CN116850287B (zh) 一种抗菌透明敷贴
US20260070873A1 (en) Cordylutenes with extraordinary effect in blue light absorption
JP7750522B2 (ja) 有機溶媒中で行われるヒアルロン酸ナトリウム塩の精製方法
CN116440061B (zh) 一种药物矿化微棒、其制备方法及应用
CN117586432A (zh) 一种透明质酸锌的制备方法及其应用
CN114366803A (zh) 一种治疗细菌性眼内炎的药物及制备方法
CN117530921A (zh) 透明质酸-瑞巴派特偶联物及其制备方法和眼用滴眼液

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20171106

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210315

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230913

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20231120

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20230913

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I